Selected renal cells (autologous, paracrine)

Class

Autologous kidney-cell therapy (REACT) — proximal-tubular-lineage cells, intrarenal injection, paracrine anti-fibrotic mechanism

Notes

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11151988/ ; https://prokidney.com/our-technology/ (rilparencel; researched 2026-08-08)

This mechanism describes a cell-based therapeutic approach for chronic kidney disease that relies on a patient's own (autologous) kidney tissue rather than a drug molecule. Cells resembling proximal tubular epithelium — a kidney compartment rich in cells that support blood vessels and secrete regenerative signals — are isolated from a small kidney biopsy, expanded, and then reinjected directly into the kidney. The therapeutic rationale rests on the biology of kidney disease progression: as nephrons are lost to injury, diabetes, or hypertension, the surrounding interstitial tissue becomes scarred (fibrotic), and this fibrosis, more than the initial injury, drives further decline in filtration capacity. Rather than acting through a single molecular receptor, these selected renal cells are thought to work by paracrine signaling — releasing a mixture of growth factors and other soluble mediators locally that can dampen the fibrotic cascade and support surviving nephron structures. This class of approach is being explored broadly across chronic kidney disease, particularly forms driven by diabetic or hypertensive injury, where slowing the fibrotic process could preserve residual kidney function longer than approaches that only manage downstream consequences such as blood pressure or glucose control.